TY - CHAP M1 - Book, Section TI - Sickle Cell Disease A1 - Schwinghammer, Terry L. A1 - DiPiro, Joseph T. A1 - Ellingrod, Vicki L. A1 - DiPiro, Cecily V. PY - 2021 T2 - Pharmacotherapy Handbook, 11e AB - Sickle cell syndromes, which can be divided into sickle cell trait (SCT) and sickle cell disease (SCD), are hereditary conditions characterized by the presence of sickle hemoglobin (HbS) in red blood cells (RBCs).SCT is the heterozygous inheritance of one normal β-globin gene producing hemoglobin A (HbA) and one sickle gene producing HbS (HbAS) gene. Individuals with SCT are asymptomatic.SCD can be of homozygous or compounded heterozygous inheritance. Homozygous HbS (HbSS) has historically been referred to as sickle cell anemia (SCA), which now also includes HbSβ0-thal due to similarities in clinical severity. The heterozygous inheritance of HbS with another qualitative or quantitative β-globin mutation results in sickle cell hemoglobin C (HbSC), sickle cell β-thalassemia (HbSβ+-thal and HbSβ0-thal), and some other rare phenotypes. SN - PB - McGraw Hill CY - New York, NY Y2 - 2024/03/28 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1178897020 ER -